Himanshu Agarwal, MD
Interventional Cardiology · Omaha, NENPI 1942280672
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $333,823 of the $541,241 with a category attached, or 61.7%. Abbott accounts for 76.3% of it on its own, with 38 other manufacturers making up the rest. Among interventional cardiology clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,254 payments — averaging $431.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$413K
- Edwards Lifesciences$32K
- Medtronic$31K
- Johnson & Johnson$26K
- Amarin Pharma, Inc.$22K
- Boston Scientific$8K
- plus $9K from 33 others
Across 266 payments — averaging $18,989 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$4.3M
- Boston Scientific$766K
- Medtronic$9K
- Biotronik Inc.$2K
What the payments were for
- Consulting fees$333,82362%
- Speaking & faculty fees$68,66513%
- Travel & lodging$89,20416%
- Food & beverage$49,5499%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER AMULET$360,962
- XARELTO$25,954
- Vascepa$21,710
- PASCAL$19,319
- COREVALVE EVOLUT R$11,364
- JETi All In One Non-Sterile Kit$9,147
- AMPLATZER TALISMAN$7,231
- IN.PACT Admiral$6,518
- AMPLATZER$6,242
- Resolute$3,818
- Omnilink Elite vascular stent system$3,388
- AMPLATZER PICCOLO$3,025
- RESOLUTE ONYX$2,100
- CoreValve Evolut$1,767
- TRICLIP$1,760
- Watchman$1,726
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,303
- GENERAL - THERAPIES$964
- (9525) Intracardiac Und$802
- SAPIEN 3 Ultra RESILIA$758
How this compares
$541,241 in reported general payments places this provider in the 95th percentile of 50 interventional cardiology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 56 | $62,050 |
| XareltoRivaroxaban | 34 | $23,228 |
| Repatha SureclickEvolocumab | 15 | $8,505 |
| JardianceEmpagliflozin | 12 | $7,444 |
| Metoprolol Succinate | 211 | $1,669 |
| ClopidogrelClopidogrel Bisulfate | 143 | $1,370 |
| Cilostazol | 17 | $1,006 |
| Rosuvastatin Calcium | 39 | $823 |
| Atorvastatin Calcium | 138 | $727 |
| Losartan Potassium | 80 | $496 |
| Carvedilol | 54 | $495 |
| Propafenone Hcl | 11 | $471 |
| Lisinopril | 64 | $470 |
| Amiodarone Hcl | 20 | $365 |
| Amlodipine Besylate | 84 | $364 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $113 | $62,05056 claims |
| Johnson & JohnsonXarelto | $26,301 | $23,22834 claims |
| Boehringer IngelheimJardiance | $46 | $7,44412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 50 interventional cardiology providers in Nebraska.
Other interventional cardiology in Omaha
- Poonam VelagapudiOmaha$142K
- Andrew GoldsweigOmaha$49K
- Jai ParekhOmaha$44K
- Scott CarolloOmaha$19K
- Shahbaz MalikOmaha$17K
- Toufik HaddadOmaha$14K
- Charles OlsonOmaha$12K
- Haysam AkkadOmaha$11K
- Ajaypaul SukhiOmaha$9K
- Filip OleszakOmaha$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.